Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 1, 2017

View Archived Issues

Benitec Biopharma begins work on two HNSCC programs

Onxeo and Institut Curie to study combining radiotherapy, DNA repair inhibitors and immunotherapy

Celgene reviews pipeline highlights of fourth quarter 2016

Phase I larotrectinib results presented at ECCO 2017

DOCK6 as an independent marker of tumor progression in gastric cancer

SETDB1 as a novel prognostic factor and potential therapeutic target in gastric cancer

Dimension Therapeutics reports topline results from phase I/II program of lead AAV candidate

Novel fragment-based screening platform for ligand and target discovery

Novel MN-array patch effectively regulates glucose levels and reduces risk of hypoglycemia in vivo

Grifols completes acquisition of Hologic NAT donor screening unit

Quadracel DTaP-IPV vaccine for children 4 through 6 years of age becomes available in the U.S.

Canada first to approve Kevzara

Catabasis reports topline results from Part B of MoveDMD study of edasalonexent

MediWound's phase II study of EscharEx meets primary endpoint

Novartis reviews pipeline progress of fourth quarter 2016

Merck KGaA discloses novel BTK inhibitors

Janssen Pharmaceutica identifies NR2B receptor antagonists

Japanese phase III trial of KHK-7580 in secondary hyperparathyroidism meets primary endpoint

Keytruda approved for first-line treatment of metastatic NSCLC in E.U.

Bayer patents mutant IDH1 inhibitors

Roche presents novel glutamate transporter EAAT3 inhibitors

Heptares Therapeutics launches new research collaboration with University of Cambridge

FDA accepts OptiNose's NDA for OPN-375

MISSION Therapeutics discloses novel deubiquylating enzymes inhibitors

First patient dosed in Angion Biomedica's phase II study of BB3

Spero Therapeutics acquires next-generation antibacterial candidates from Pro Bono Bio

Gemphire Therapeutics reports interim data from phase IIb study of gemcabene in HoFH

Tenax reports topline data from phase III trial of levosimendan in cardiac surgery

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...